חוב לטווח קצר להון AnaptysBio, Inc. (ANAB)

AnaptysBio, Inc. develops immunological treatments through alliances with industry behemoths and patent acquisitions. This chart of the debt-to-equity ratio captures a value of 3.34. The company focuses on therapies for severe inflammatory processes, leveraging deep biotechnological expertise. The financial model relies on licensing fees, as market pricing power depends on the success of external partners.

This ratio measures the company's dependence on current liabilities by comparing the volume of loans maturing within one year to the amount of equity to assess liquidity risk. By analyzing the short-term debt-to-equity ratio, an investor can determine how stable the AnaptysBio (ANAB) royalties from partner drugs are for covering operational debts without compromising the development of its biopharmaceutical portfolio.